Table 3
Component: Lipid S4 | Initial S4 mol%: 45.8891 | OS4 mol%: 28.4192 | MW used (g/mol): 861.65
sales@dcchemicals.com
Lipid S4
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 3
Component: DOPE | Initial S4 mol%: 22.9446 | OS4 mol%: 28.4192 | MW used (g/mol): 744.03
Table 3
Component: Cholesterol | Initial S4 mol%: 30.5927 | OS4 mol%: 42.6288 | MW used (g/mol): 386.65
Table 3
Component: DMG-PEG2k | Initial S4 mol%: 0.5736 | OS4 mol%: 0.5329 | MW used (g/mol): 2507
Table 4
Formulation: Initial S4 | Size: ~120 nm | PDI: ~0.10 | Encapsulation: ~83% | Zeta potential: ~−7 mV | Source: SI p. 7, Figs. S2–S3
Table 4
Formulation: OS4 | Size: ~100 nm | PDI: ~0.03 | Encapsulation: Not individually stated | Zeta potential: ~−7 mV | Source: Main p. 5, Fig. 3B; SI p. 8, Fig. S5
Table 4
Formulation: OS4T | Size: ~130 nm | PDI: ~0.20 | Encapsulation: Not individually stated | Zeta potential: ~+17 mV | Source: Main p. 5, Fig. 3B; SI p. 8, Fig. S5
Table 5
Formulation / assay: OS4 · brain FLuc | Experimental conditions: C57BL/6J mice; IV 0.6 mg mRNA/kg; 6 h; n = 3 | Reported result: 13.3-fold MC3, 12.5-fold SM-102, 9.6-fold ALC-0315, and 2-fold initial S4. | Source: Main pp. 3–4, Fig. 2D–E
Table 5
Formulation / assay: OS4T · brain FLuc | Experimental conditions: Same dose and endpoint; separate comparator panels; n = 3 | Reported result: 12.7-fold OS4 in Fig. 3C. In Fig. 3D–E, 59.1-fold MC3 and 17.2-fold MC3T. | Source: Main pp. 3, 5, Fig. 3C–E
Table 5
Formulation / assay: OS4 / OS4T · brain-cell GFP | Experimental conditions: C57BL/6J mice; IV 1 mg mRNA/kg; 12 h; n = 3 | Reported result: OS4 improved GFP-positive fractions versus MC3 by about 8× in neurons, 4× in astrocytes, 6× in microglia and 3× in BCECs. OS4T further improved neurons, microglia and BCECs. | Source: Main p. 6, Fig. 4A
Table 5
Formulation / assay: OS4T · Cre reporter activation | Experimental conditions: Ai14 mice; one IV dose, 1 mg Cre mRNA/kg; Results specify day 7 | Reported result: tdTomato-positive neurons 13.1 ± 1.2%; astrocytes 9.9 ± 1.2%; microglia 10.2 ± 0.4%; BCECs 11.6 ± 1.6%. MC3: <2%. | Source: Main pp. 6–7, Fig. 4B–C
Table 5
Formulation / assay: OS4T–eIL-12 · orthotopic GBM | Experimental conditions: CT-2A-Luc tumors in C57BL/6J mice; IV 1 mg mRNA/kg on days 3, 8 and 13; survival n = 7 | Reported result: Median survival 37 days versus 17 days for PBS. This result requires Tat-conjugated OS4T and engineered IL-12 mRNA. | Source: Main pp. 7–8, Fig. 5D–F
Table 5
Formulation / assay: OS4 / OS4T · acute tolerability | Experimental conditions: IV FLuc mRNA 1 mg/kg; AST/ALT/BUN at 24 and 48 h; n = 3; histology at 48 h | Reported result: Biomarkers were comparable to PBS; no notable tissue pathology in the reported short-term mouse experiment. | Source: Main pp. 5–6, 10; SI p. 12, Fig. S11
Table 6
S4 mass: 10 mg | Amount (μmol): 11.6056 | Final volume: 1 mM: 11.6056 mL | Final volume: 5 mM: 2.3211 mL | Final volume: 10 mM: 1.1606 mL
Table 6
S4 mass: 25 mg | Amount (μmol): 29.0141 | Final volume: 1 mM: 29.0141 mL | Final volume: 5 mM: 5.8028 mL | Final volume: 10 mM: 2.9014 mL
Table 6
S4 mass: 50 mg | Amount (μmol): 58.0282 | Final volume: 1 mM: 58.0282 mL | Final volume: 5 mM: 11.6056 mL | Final volume: 10 mM: 5.8028 mL
Table 6
S4 mass: 100 mg | Amount (μmol): 116.0564 | Final volume: 1 mM: 116.0564 mL | Final volume: 5 mM: 23.2113 mL | Final volume: 10 mM: 11.6056 mL
Table 6
S4 mass: 250 mg | Amount (μmol): 290.1410 | Final volume: 1 mM: 290.1410 mL | Final volume: 5 mM: 58.0282 mL | Final volume: 10 mM: 29.0141 mL